Hormonal Therapy of Breast Cancer With Special Reference to Masteril Therapy

S Afr Med J. 1975 Nov 15;49(49):2036-40.


From 1968 to 1972, a trial of a new agent, drostanolone propionate (Masteril), was conducted. This agent was tested against oophorectomy in a group of premenopausal patients, against nandrolone phenylpropionate (Durabolin) in a perimenopausal group, and against ethinyl oestradiol in a postmenopausal group. In the premenopausal group, 44% responded to Masteril and 22% to oophorectomy. In the perimenopausal group, 34,5% responded to Masteril and 39% to Durabolin. In the postmenopausal group, 57% responded to oestrogens and 38,5% to Masteril. The side-effects of Masteril are generally not serious and rarely contra-indicate its use. Masteril has been shown to be a useful and safe agent for all age groups, even though it may appear to be less effective than oestrogens in the postmenopausal patients.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Androgens / adverse effects
  • Androstanols / analogs & derivatives*
  • Androstanols / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / therapy
  • Castration
  • Ethinyl Estradiol / adverse effects
  • Ethinyl Estradiol / therapeutic use
  • Female
  • Humans
  • Menopause
  • Middle Aged
  • Nandrolone / adverse effects
  • Nandrolone / therapeutic use


  • Androgens
  • Androstanols
  • Ethinyl Estradiol
  • Nandrolone